• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP
Click for more information
0.00% 21.5¢

CYNATA THERAPEUTICS LIMITED - Announcements

Market Cap $34.32M  ! watchlist Created with Sketch. Add to my watchlist

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CYP CYP & FUJIFILM Sign Non-Binding Terms Sheet-CYP.AX PRICE SENSITIVE05/09/16
CYP Trading Halt-CYP.AX PRICE SENSITIVE02/09/16
CYP Appendix 4G-CYP.AX 19/08/16
CYP Appendix 4E & Financial Statements-CYP.AX PRICE SENSITIVE19/08/16
CYP Expiry of Unlisted Options-CYP.AX 17/08/16
CYP Cynata Files Application to Commence Phase 1 Clinical Trial-CYP.AX PRICE SENSITIVE01/08/16
CYP Activities Report & Appendix 4C-CYP.AX PRICE SENSITIVE29/07/16
CYP Cynata Receives Investment Offer from Regience-CYP.AX PRICE SENSITIVE30/06/16
CYP Cynata Prepares for Phase 1 Clinical Trial-CYP.AX PRICE SENSITIVE21/06/16
CYP Initial Director's Interest Notice-CYP.AX 09/06/16
CYP Cynata Appoints Paul K Wotton Ph.D. to Board of Directors-CYP.AX 09/06/16
CYP Cynata Enters Agreement with apceth GmbH & Co KG-CYP.AX PRICE SENSITIVE09/05/16
CYP CYP Manufactures CT Product-Files Further Patent Application-CYP.AX PRICE SENSITIVE05/05/16
CYP Decision to Grant Patent for Cymerus MSC Technology in Japan-CYP.AX PRICE SENSITIVE02/05/16
CYP Cynata & Regience Extend Entitlement Period-CYP.AX PRICE SENSITIVE29/04/16
CYP Quarterly Activities Report & Appendix 4C-CYP.AX PRICE SENSITIVE29/04/16
CYP Compelling Results from Pre-Clinical Stem Cell Study in GvHD-CYP.AX PRICE SENSITIVE07/04/16
CYP Cynata Enters Agreement for Strategic Alliance in JapanPRICE SENSITIVE03/03/16
CYP Appendix 4D & Half-Year Financial StatementsPRICE SENSITIVE26/02/16
CYP Appendix 3B22/02/16
CYP Cynata Receives $930k R&D Tax Incentive RefundPRICE SENSITIVE16/02/16
CYP Quarterly Activities Report & Appendix 4CPRICE SENSITIVE29/01/16
CYP CYP Receives Favourable Advice from UK Regulatory AuthorityPRICE SENSITIVE28/01/16
CYP Cynata CLI Study Published in Peer Reviewed JournalPRICE SENSITIVE12/01/16
CYP Cynata Enters Letter of Intent for a Commercial PartnershipPRICE SENSITIVE17/12/15
CYP Appendix 3B16/12/15
CYP Rodman & Renshaw Initiates Cynata Research Coverage08/12/15
CYP CYP Enters Letter of Intent for Strategic Alliance in JapanPRICE SENSITIVE03/12/15
CYP Expiry of Unlisted Options01/12/15
CYP Results of Annual General Meeting11/11/15
CYP MD's AGM Presentation11/11/15
CYP Restricted Securities to be Release from Escrow06/11/15
CYP Cynata Engages CRO to Conduct GvHD Clinical TrialPRICE SENSITIVE05/11/15
CYP Activities Report & Appendix 4C29/10/15
CYP CYP in Major New Collaboration for Cell Therapy for CancerPRICE SENSITIVE14/10/15
CYP Annual Report to Shareholders06/10/15
CYP Notice of Annual General Meeting/Proxy Form06/10/15
CYP Cynata to Present at Rodman & Renshaw Investment Conference07/09/15
CYP SeeThruEquity Initiates Cynata Reasearch Coverage03/09/15
CYP Appendix 4G21/08/15
CYP Appendix 4E & FInancial StatementsPRICE SENSITIVE21/08/15
CYP Activities Report & Appendix 4CPRICE SENSITIVE30/07/15
CYP Cynata in Heart Disease Collaboration with Uni of SydneyPRICE SENSITIVE30/07/15
CYP Information Required Under Listing Rule 3.10.5A17/07/15
CYP Section 708A Notice17/07/15
CYP Appendix 3B17/07/15
CYP Section 708A Notice15/07/15
CYP Private Placement to US Institutional Investors CompletedPRICE SENSITIVE15/07/15
CYP R&D Tax IncentivePRICE SENSITIVE25/05/15
CYP Cynata - Cymerus Progress ReportPRICE SENSITIVE21/05/15
CYP Response to ASX QueryPRICE SENSITIVE08/05/15
CYP Activity Report & Appendix 4CPRICE SENSITIVE30/04/15
CYP Appendix 3Y-John Chiplin30/03/15
CYP Cynata CEO to Chair World Congress Session on Stem Cells18/03/15
CYP Appendix 3Y-Stewart Washer16/03/15
CYP Executive Services Contracts Renewed/Vesting Conditions Met16/03/15
CYP Commences Further Stage of Stem Cell Manufacturing ProgramPRICE SENSITIVE12/03/15
CYP Director Options Vesting Condition Met06/03/15
CYP Cynata Presenting at 8th Annual ASX Spotlight New York 201505/03/15
CYP Appendix 4D & Half-Year Financial StatementsPRICE SENSITIVE26/02/15
CYP CYP Investor Presentation-February 201523/02/15
CYP BBY Updates Cynata Research Coverage20/02/15
CYP Cynata Achieves Major Stem Cell Manufacturing MilestonePRICE SENSITIVE19/02/15
CYP Trading HaltPRICE SENSITIVE17/02/15
CYP Cynata Engages CRO to Plan Clinical Trial16/02/15
CYP Change of Share Registry13/02/15
CYP Cynata Engages Leading US Investor Relations FirmPRICE SENSITIVE12/02/15
CYP Cynata Partners with Univeristy of Western AustraliaPRICE SENSITIVE03/02/15
CYP Activity Report & Appendix 4CPRICE SENSITIVE30/01/15
CYP Top 20 Shareholders15/01/15
CYP Section 708A Notice14/01/15
CYP Appendix 3B14/01/15
CYP Section 708A Notice06/01/15
CYP Completion of Exercise of Underwritten Listed Options06/01/15
CYP Section 708A Notice31/12/14
CYP Appendix 3B-Exercise of Listed Options31/12/14
CYP Section 708A Notice24/12/14
CYP Appendix 3B-Exercise of Listed Options24/12/14
CYP Appendix 3Y-Peter Webse18/12/14
CYP Section 708A Notice18/12/14
CYP Appendix 3B-Exercise of Listed Options18/12/14
CYP Section 708A Notice11/12/14
CYP Appendix 3B-Exercise of Listed Options11/12/14
CYP Section 708A Notice05/12/14
CYP Appendix 3B - Exercise of Listed Options05/12/14
CYP CYP to Present at Major International Stem Cell Conference04/12/14
CYP Notification of Expiry of Listed Options01/12/14
CYP Cynata Listed Options Fully UnderwrittenPRICE SENSITIVE25/11/14
CYP Appendix 3B-Release of Shares from Escrow24/11/14
CYP Appendix 3X-Dr John Chiplin18/11/14
CYP Appendix 3Z-Howard Digby18/11/14
CYP Cynata Board Changes Implemented18/11/14
CYP Results of Annual General Meeting18/11/14
CYP CEO Presentation to AGM18/11/14
CYP Section 708A Notice14/11/14
CYP Appendix 3B-Exercise of Listed Options14/11/14
CYP Section 708A Notice12/11/14
CYP Appendix 3B - Exercise of Listed Options12/11/14
CYP Restricted Securities to be Released from ASX Escrow07/11/14
CYP Australian Patent for Core Cynata TechnologyPRICE SENSITIVE06/11/14
CYP CYP & FUJIFILM Sign Non-Binding Terms Sheet-CYP.AX
05/09/16PRICE SENSITIVE
CYP Trading Halt-CYP.AX
02/09/16PRICE SENSITIVE
CYP Appendix 4G-CYP.AX
19/08/16
CYP Appendix 4E & Financial Statements-CYP.AX
19/08/16PRICE SENSITIVE
CYP Expiry of Unlisted Options-CYP.AX
17/08/16
CYP Cynata Files Application to Commence Phase 1 Clinical Trial-CYP.AX
01/08/16PRICE SENSITIVE
CYP Activities Report & Appendix 4C-CYP.AX
29/07/16PRICE SENSITIVE
CYP Cynata Receives Investment Offer from Regience-CYP.AX
30/06/16PRICE SENSITIVE
CYP Cynata Prepares for Phase 1 Clinical Trial-CYP.AX
21/06/16PRICE SENSITIVE
CYP Initial Director's Interest Notice-CYP.AX
09/06/16
CYP Cynata Appoints Paul K Wotton Ph.D. to Board of Directors-CYP.AX
09/06/16
CYP Cynata Enters Agreement with apceth GmbH & Co KG-CYP.AX
09/05/16PRICE SENSITIVE
CYP CYP Manufactures CT Product-Files Further Patent Application-CYP.AX
05/05/16PRICE SENSITIVE
CYP Decision to Grant Patent for Cymerus MSC Technology in Japan-CYP.AX
02/05/16PRICE SENSITIVE
CYP Cynata & Regience Extend Entitlement Period-CYP.AX
29/04/16PRICE SENSITIVE
CYP Quarterly Activities Report & Appendix 4C-CYP.AX
29/04/16PRICE SENSITIVE
CYP Compelling Results from Pre-Clinical Stem Cell Study in GvHD-CYP.AX
07/04/16PRICE SENSITIVE
CYP Cynata Enters Agreement for Strategic Alliance in Japan
03/03/16PRICE SENSITIVE
CYP Appendix 4D & Half-Year Financial Statements
26/02/16PRICE SENSITIVE
CYP Appendix 3B
22/02/16
CYP Cynata Receives $930k R&D Tax Incentive Refund
16/02/16PRICE SENSITIVE
CYP Quarterly Activities Report & Appendix 4C
29/01/16PRICE SENSITIVE
CYP CYP Receives Favourable Advice from UK Regulatory Authority
28/01/16PRICE SENSITIVE
CYP Cynata CLI Study Published in Peer Reviewed Journal
12/01/16PRICE SENSITIVE
CYP Cynata Enters Letter of Intent for a Commercial Partnership
17/12/15PRICE SENSITIVE
CYP Appendix 3B
16/12/15
CYP Rodman & Renshaw Initiates Cynata Research Coverage
08/12/15
CYP CYP Enters Letter of Intent for Strategic Alliance in Japan
03/12/15PRICE SENSITIVE
CYP Expiry of Unlisted Options
01/12/15
CYP Results of Annual General Meeting
11/11/15
CYP MD's AGM Presentation
11/11/15
CYP Restricted Securities to be Release from Escrow
06/11/15
CYP Cynata Engages CRO to Conduct GvHD Clinical Trial
05/11/15PRICE SENSITIVE
CYP Activities Report & Appendix 4C
29/10/15
CYP CYP in Major New Collaboration for Cell Therapy for Cancer
14/10/15PRICE SENSITIVE
CYP Annual Report to Shareholders
06/10/15
CYP Notice of Annual General Meeting/Proxy Form
06/10/15
CYP Cynata to Present at Rodman & Renshaw Investment Conference
07/09/15
CYP SeeThruEquity Initiates Cynata Reasearch Coverage
03/09/15
CYP Appendix 4G
21/08/15
CYP Appendix 4E & FInancial Statements
21/08/15PRICE SENSITIVE
CYP Activities Report & Appendix 4C
30/07/15PRICE SENSITIVE
CYP Cynata in Heart Disease Collaboration with Uni of Sydney
30/07/15PRICE SENSITIVE
CYP Information Required Under Listing Rule 3.10.5A
17/07/15
CYP Section 708A Notice
17/07/15
CYP Appendix 3B
17/07/15
CYP Section 708A Notice
15/07/15
CYP Private Placement to US Institutional Investors Completed
15/07/15PRICE SENSITIVE
CYP R&D Tax Incentive
25/05/15PRICE SENSITIVE
CYP Cynata - Cymerus Progress Report
21/05/15PRICE SENSITIVE
CYP Response to ASX Query
08/05/15PRICE SENSITIVE
CYP Activity Report & Appendix 4C
30/04/15PRICE SENSITIVE
CYP Appendix 3Y-John Chiplin
30/03/15
CYP Cynata CEO to Chair World Congress Session on Stem Cells
18/03/15
CYP Appendix 3Y-Stewart Washer
16/03/15
CYP Executive Services Contracts Renewed/Vesting Conditions Met
16/03/15
CYP Commences Further Stage of Stem Cell Manufacturing Program
12/03/15PRICE SENSITIVE
CYP Director Options Vesting Condition Met
06/03/15
CYP Cynata Presenting at 8th Annual ASX Spotlight New York 2015
05/03/15
CYP Appendix 4D & Half-Year Financial Statements
26/02/15PRICE SENSITIVE
CYP CYP Investor Presentation-February 2015
23/02/15
CYP BBY Updates Cynata Research Coverage
20/02/15
CYP Cynata Achieves Major Stem Cell Manufacturing Milestone
19/02/15PRICE SENSITIVE
CYP Trading Halt
17/02/15PRICE SENSITIVE
CYP Cynata Engages CRO to Plan Clinical Trial
16/02/15
CYP Change of Share Registry
13/02/15
CYP Cynata Engages Leading US Investor Relations Firm
12/02/15PRICE SENSITIVE
CYP Cynata Partners with Univeristy of Western Australia
03/02/15PRICE SENSITIVE
CYP Activity Report & Appendix 4C
30/01/15PRICE SENSITIVE
CYP Top 20 Shareholders
15/01/15
CYP Section 708A Notice
14/01/15
CYP Appendix 3B
14/01/15
CYP Section 708A Notice
06/01/15
CYP Completion of Exercise of Underwritten Listed Options
06/01/15
CYP Section 708A Notice
31/12/14
CYP Appendix 3B-Exercise of Listed Options
31/12/14
CYP Section 708A Notice
24/12/14
CYP Appendix 3B-Exercise of Listed Options
24/12/14
CYP Appendix 3Y-Peter Webse
18/12/14
CYP Section 708A Notice
18/12/14
CYP Appendix 3B-Exercise of Listed Options
18/12/14
CYP Section 708A Notice
11/12/14
CYP Appendix 3B-Exercise of Listed Options
11/12/14
CYP Section 708A Notice
05/12/14
CYP Appendix 3B - Exercise of Listed Options
05/12/14
CYP CYP to Present at Major International Stem Cell Conference
04/12/14
CYP Notification of Expiry of Listed Options
01/12/14
CYP Cynata Listed Options Fully Underwritten
25/11/14PRICE SENSITIVE
CYP Appendix 3B-Release of Shares from Escrow
24/11/14
CYP Appendix 3X-Dr John Chiplin
18/11/14
CYP Appendix 3Z-Howard Digby
18/11/14
CYP Cynata Board Changes Implemented
18/11/14
CYP Results of Annual General Meeting
18/11/14
CYP CEO Presentation to AGM
18/11/14
CYP Section 708A Notice
14/11/14
CYP Appendix 3B-Exercise of Listed Options
14/11/14
CYP Section 708A Notice
12/11/14
CYP Appendix 3B - Exercise of Listed Options
12/11/14
CYP Restricted Securities to be Released from ASX Escrow
07/11/14
CYP Australian Patent for Core Cynata Technology
06/11/14PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
21.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $34.32M
Open High Low Value Volume
21.5¢ 21.5¢ 21.5¢ $5.375K 25K

Buyers (Bids)

No. Vol. Price($)
3 27580 21.5¢
 

Sellers (Offers)

Price($) Vol. No.
22.5¢ 15135 2
View Market Depth
Last trade - 12.20pm 29/11/2024 (20 minute delay) ?
CYP (ASX) Chart

Top Stories

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Resolute Mining Ltd has told investors that a second payment has been made to the Mali government following the detention of three employees
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.